Context Therapeutics (CNTX) Retained Earnings (2020 - 2026)

Context Therapeutics has disclosed Retained Earnings across 7 years of filings, most recently posting -$139.6 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$139.6 million, down 40.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$139.6 million (down 40.44% YoY), and the FY2025 annual result was -$130.9 million, down 38.11% from the prior year.
• Retained Earnings came in at -$139.6 million for Q1 2026 at Context Therapeutics, down from -$130.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$32.7 million in Q1 2022 to a low of -$139.6 million in Q1 2026.
• The 5-year median for Retained Earnings is -$71.7 million (2024), against an average of -$77.5 million.
• Across the five-year window, Retained Earnings tumbled 54.58% in 2022 and slipped 28.94% in 2025, its largest moves.
• Context Therapeutics' Retained Earnings stood at -$44.1 million in 2022, then tumbled by 54.35% to -$68.1 million in 2023, then plunged by 39.27% to -$94.8 million in 2024, then plunged by 38.11% to -$130.9 million in 2025, then decreased by 6.64% to -$139.6 million in 2026.
• The last three Retained Earnings figures came in at -$139.6 million (Q1 2026), -$130.9 million (Q4 2025), and -$117.9 million (Q3 2025), per Business Quant data.